Lupin receives FDA approval for Clomipramine HCl Capsules

Deepthi | Myequity news | Date : 26-11-2018 15:50:00 IST

Pharma major Lupin received approval for its Clomipramine Hydrochloride Capsules USP, 25 mg, 50 mg, and 75 mg from the United States Food and Drug Administration (FDA) to market a generic version of SpecGx LLC’s Anafranil Capsules, 25 mg, 50 mg, and 75 mg.

Lupin’s Clomipramine Hydrochloride Capsules USP, 25 mg, 50 mg, and 75 mg is the generic version of SpecGx LLC’s Anafranil Capsules, 25 mg, 50 mg, and 75 mg. It is indicated for the treatment of obsessions and compulsions in patients with Obsessive-Compulsive Disorder (OCD).

Anafranil Capsules, 25 mg, 50 mg, and 75 mg had annual sales of approximately USD 109.6 millionin the US (IQVIA MAT September 2018).


About Lupin Limited


Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.


More from Myequity